

REGISTRY OF PATIENTS HOSPITALIZED WITH PULMONARY EMBOLISM

Thesis

Submitted for Partial Fulfillment of Master Degree in
Cardiology

Presented by

Ahmed Mostafa Torki

M.B.,B.ch

Under supervision of

Professor Doctor Nabil Mahmoud Farag

Professor of Cardiology

Ain Shams University

Doctor Sameh Saleh Sabet

Assistant Professor of Cardiology

Ain Shams University

Doctor Viola William Keddeas

Fellow of Cardiology

Ain Shams University

Faculty of Medicine

Ain Shams University

٢٠١٠

Acknowledgements

This thesis would have not been possible without the guidance and support of my professors and colleagues.

*I would like to express my deepest gratitude to **Professor Doctor Nabil Farag** who has supported me throughout my work with his knowledge, guidance and patience. I thank him for all his support and I hope that I will rise to his expectation.*

*I would also like to express my appreciation to **Doctor Sameh Sabet** for his keen supervision and direct guidance throughout my work. He has always encouraged me to do my best.*

*It is a pleasure to thank **Dr. Viola Williams** for her guidance and advice from the start of my thesis to the end.*

*I'm also grateful to **Professor Doctor Ramez Guindy and Professor Doctor Wael El Naggar** for their precious time and effort.*

A special thanks to my colleagues in Ain Shams University Hospital and Dar al Fouad Hospital for their collaboration.

Finally I would like to express my love and gratitude to my beloved family for their endless support and encouragement throughout my whole life.

List of Contents

	Page
Acknowledgements	
Introduction	۱
Aim of work	۵
Review of literature:	
• Historical perspective	۶
• Epidemiology	۸
• Risk factors	۱۲
• Pathophysiology	۲۲
• Diagnosis:	
○ Symptoms and signs	۲۹
○ Differential diagnosis	۳۲
○ Severity of pulmonary embolism	۳۲
○ Markers of myocardial injury	۳۴
○ Assessment of clinical probability	۳۶
• Investigations:	
○ D-dimer	۳۹
○ Arterial Blood Gases	۴۰
○ Electrocardiogram	۴۱
○ Chest radiography	۴۲
○ Echocardiography	۴۳
○ Venous Ultrasonography	۴۵

○ Ventilation–perfusion scintigraphy	٤٧
○ Chest computed tomography	٤٨
○ Pulmonary angiography	٥٠
• Diagnostic strategies	٥٢
• Treatment:	
○ Haemodynamic and respiratory support	٥٥
○ Thrombolysis	٥٦
○ Anticoagulation	٦٠
○ Inferior Vena Caval Filters	٧٢
○ Surgical pulmonary embolectomy	٧٣
○ Percutaneous catheter embolectomy and fragmentation	٧٤
• Prevention	٧٦
Patients and methods	٧٨
Results	٨٧
Discussion	١١٤
Conclusion	١٢٣
Recommendations	١٢٤
Limitations	١٢٥
Summary	١٢٦
References	١٢٩
Arabic summary	_____

List of Tables

Table No.	Page
Table (١): Major Acquired Risk Factors for Venous Thromboembolism	١٢
Table (٢): Prevalence of symptoms and signs in patients with suspected PE according to final diagnoses	٣١
Table (٣): Principal markers useful for risk stratification in acute pulmonary embolism	٣٣
Table (٤): Wells score	٣٨
Table (٥): ECG findings of PE	٤٢
Table (٦): Echocardiographic Signs of PE	٤٥
Table (٧): Thrombolysis used in PE	٥٩
Table (٨): Containdications of Thrombolysis	٦٠
Table (٩): UFH dose	٦٣
Table (١٠): Demographic data of studied patients	٨٨
Table (١١): Risk factors and Co-morbidities of studied patients	٩٠
Table (١٢): Symptoms of studied patients	٩١

Table (١٣):	Signs of studied patients	٩٣
Table (١٤):	Well's score of studied patients	٩٤
Table (١٥):	ECG findings of studied patients	٩٦
Table (١٦):	CXR findings in studied patients	٩٧
Table (١٧):	Tricuspid regurge % in studied patients	٩٨
Table (١٨):	ECHO findings in studied patients	١٠٠
Table (١٩):	Workup of Hypercoagulable state in studied patients	١٠٤
Table (٢٠):	ABG's of studied patients	١٠٥
Table (٢١):	Subcutaneous regimens of low molecular weight heparin and fondaparinux used in treatment of studied patients	١٠٧
Table (٢٢):	Clinical predictors of Fatal Pulmonary Embolism (Single Predictor)	١١٣

List of Figures

Figure No.	Page
Figure (١): Virchow's Triad	٧
Figure (٢): Pathophysiology of PE	٢٣
Figure (٣): Diagnostic algorithm for patients with suspected high-risk PE, i.e. presenting with shock or hypotension	٥٣
Figure (٤): Diagnostic algorithm for patients with suspected non-high-risk PE (i.e. without shock and hypotension)	٥٤
Figure (٥): Percentage (%) of Dyspnea in studied patients	٩٢
Figure (٦): Percentage (%) of Sinus tachycardia in studied patients	٩٥
Figure (٧): ٥٠ years old, male patient, presenting with signs of DVT and dyspnea. ECG was done showing S١Q٣T٣ pattern and sinus tachycardia	٩٦
Figure (٨): MDCT images of ٣٢ years old male patient, who presented with shortness of breath, chest pain. Central	

List of Abbreviations

anti-Xa	Anti-factor Xa activity
aPTT	Activated partial thromboplastin time
BNP	Brain natriuretic peptide
CI	Confidence interval
CT	Computed tomography
CTEPH	Chronic thromboembolic pulmonary hypertension
CTPH	Chronic thromboembolic pulmonary hypertension CTPH
CUS	Compression venous ultrasonography
DVT	Deep venous thrombosis
ECG	Electrocardiogram
HIT	Heparin-induced thrombocytopenia
ICOPER	International Cooperative Pulmonary Embolism Registry
INR	International normalized ratio
IVC	Inferior vena cava
LMWH	Low molecular weight heparin
LV	Left ventricle

MDCTMulti-detector computed tomography

MIMyocardial infarction

NPVNegative predictive value

NT-proBNP N-terminal proBNP

OROdds ratio

PaO₂Arterial oxygen pressure

PEPulmonary embolism

PIOPEDProspective Investigation On Pulmonary
Embolism Diagnosis study

PPVPositive predictive value

RVRight ventricle

RVSPRight ventricular systolic pressure RVSP

UFHUnfractionated heparin

V/Q scanVentilation–perfusion scintigraphy

VKAVitamin K antagonist

VTVenous thrombosis

VTE.....Venous thromboembolism

Introduction

Pulmonary embolism (PE) is known to be a major cause of death in patients with venous thromboembolism. Yet in cohort studies, randomized clinical trials, and general reviews on this topic, the incidence of fatal PE varied from 1% to 4%. This variability, mainly related to the type of patients studied, highlights that venous thromboembolism is a heterogeneous disease with various presentations and prognoses. (*Wells et al 2000*)

The key to appropriate therapy is therefore risk stratification to identify patients at high risk of death who should receive specific therapeutic management. This step is all the more important in that the use of generally recommended treatments, such as administration of fibrinolytic drugs or placement of vena cava filters in high-risk patients may be complicated by severe adverse events. However, to date, the clinical variables indicating a high risk of fatal PE in patients with venous thromboembolism remain largely unknown. (*Goldhaber et al., 2004*)

Acute pulmonary embolism is a major cause of complications and death associated with surgery, injury, and medical illnesses, and it may occur after long-distance air travel. Venous thromboembolism is responsible for up to 15% of all in-hospital deaths, and it also accounts for 20 to 30% of deaths associated with pregnancy and delivery in the United States and Europe. Overall, the annual incidence of pulmonary embolism has been reported to range between 23 and 69 cases per 100,000 population. (*Silverstein et al., 1991*)

Case fatality rates vary widely depending on the severity of the disease (*Kasper et al., 1991*); at an average case fatality rate within 2 weeks of diagnosis of approximately 11%, the Surgeon General estimates that venous thromboembolism accounts for at least 100,000 deaths each year. (*Goldhaber et al., 2004*)

Pulmonary embolism is a commonly encountered disorder, usually precipitated by deep venous thrombosis, and is associated with significant morbidity and mortality. It accounts for 10% of all deaths in hospital, and is a major contributing factor in a further 10%. (*Linblad et al., 1991*) It can result in

pulmonary hypertension and right ventricular dysfunction, and its mortality rate of approximately 14%, (*Wessler et al.*, 1986) has changed little over the last 30 years. (*Linblad et al.*, 1991)

Recognized venous thromboembolism (pulmonary embolism and deep venous thrombosis) is responsible for more than 200,000 hospitalizations and approximately 50,000 deaths per year in the United States.

Because it is difficult to diagnose, the true incidence of pulmonary embolism is unknown, but it is estimated that approximately 60,000 cases occur annually. (*Wolfe et al.*, 1998)

Despite this high incidence, the diagnosis of pulmonary embolism continues to be difficult primarily because of the notorious vagaries of symptoms and signs in its presentation. (*Manolis et al.*, 1990)

Most patients who succumb to pulmonary embolism do so within the first few hours of the event. In patients who survive, recurrent embolism and death can be prevented with prompt diagnosis and therapy. Unfortunately, the diagnosis is often missed because

patients with pulmonary embolism present with nonspecific signs and symptoms. If left untreated, approximately one third of patients who survive an initial pulmonary embolism die from a subsequent embolic episode. (*Burge et al.*, 2008)

The most important conceptual advance regarding pulmonary embolism over the last several decades has been the realization that pulmonary embolism is not a disease; rather, pulmonary embolism is a complication of venous thromboembolism, most commonly deep venous thrombosis (DVT). Virtually every physician who is involved in patient care (eg, internist, family physician, orthopedic surgeon, gynecologic surgeon, urologic surgeon, pulmonary subspecialist, cardiologist) encounters patients who are at risk for venous thromboembolism, and therefore at risk for pulmonary embolism. (*Kuklina et al.* 2009)

Aim of Work

Aim of this registry is to follow-up and assess a broad sample of patients hospitalized with confirmed or high clinical probability of pulmonary embolism regarding risk factors, clinical presentation, diagnosis, management and outcome.

Historical Perspective

In 1846, Rudolf Virchow, then 30 years old, described the triad of stasis, vessel wall injury, and hypercoagulability and its association with the development of venous thrombosis. (Figure 1) This association is perhaps one of the most enduring themes in medicine. Every scenario recognized to date that can be considered a risk factor for this disease is derived from this triad. The presence of risk factors may lead to suspicion of the presence of deep venous thrombosis (DVT) or pulmonary embolism, collectively referred to as venous thromboembolism (VTE), as well as being critical in determining appropriate prophylaxis among patients at risk.

In 1880, Beniamino Luzzatto described at least 160 cases of PE in a manuscript entitled “Embolism of the Pulmonary Artery”, in which he emphasized the predilection for the lower lobes and the predisposing role of stasis and preexisting cardiopulmonary disease.